Overall, the observed incidence of hypophysitis was 6.4% for combination therapy, 3.2% for CTLA-4 inhibitors, 0.4% for PD-1 inhibitors, and less than 0.1% for PD-L1 inhibitors [61,62]. The gene discussed is CD274; the disease is hypophysitis.